Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone609-662-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$91.25 million
Profitability
Miscellaneous
Employees508
Next Earnings Date11/12/2019 (Confirmed)
OptionableOptionable
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.34). The biopharmaceutical company had revenue of $44.13 million for the quarter, compared to the consensus estimate of $41.14 million. Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. The business's quarterly revenue was up 107.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.33) EPS. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
How can I listen to Amicus Therapeutics' earnings call?
Amicus Therapeutics will be holding an earnings conference call on Tuesday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics updated its third quarter 2019 earnings guidance on Thursday, October, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $48-48 million, compared to the consensus revenue estimate of $45.43 million.
What price target have analysts set for FOLD?
7 brokerages have issued 1 year target prices for Amicus Therapeutics' shares. Their predictions range from $12.59 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $18.93 in the next twelve months. This suggests a possible upside of 124.3% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.
What is the consensus analysts' recommendation for Amicus Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.
What are Wall Street analysts saying about Amicus Therapeutics stock?
Here are some recent quotes from research analysts about Amicus Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our current 12-month, $18 price target on shares of Amicus is derived from a 13-year DCF-based, sum-of-the-parts analysis driven by: beta of 1.70; terminal growth rate of 0.5%; risk premium of 4.93%; estimated WACC of 10.8%; and tax rate of 12.5% beginning in FY 2030. Galafold and AT- GAA at 42% each, plus the two Batten disease programs programs at a combined 16%, make up our rNPV. For AT-GAA, we assume a POS of 70%, whereas for CLN6 we assume a 45% POS and assign a 10% POS for CLN3." (8/1/2019)
- 2. According to Zacks Investment Research, "2018 was a great year for Amicus as it received U.S. approval for its only marketed drug Galafold. The company expanded its pipeline to include 14 new gene-therapy programs for rare metabolic diseases. The company is on track to achieve its 2019 key priorities, including the global Fabry launch, Pompe late-stage development program, and development of the gene-therapy pipeline. With a very successful, now global, commercial precision medicine product in Fabry disease, a late-stage program with Breakthrough Therapy designation in late onset Pompe disease and 14 gene therapy programs for rare diseases in development, the company is strongly positioned to achieve its vision. However, it depends heavily on Galafold sales, which is a concern. Shares of the company have underperformed the industry in the past year." (5/3/2019)
- 3. Cantor Fitzgerald analysts commented, "We rate Amicus Therapeutics Overweight. Amicus focuses on treatments for lysosomal storage disorders and rare diseases. We foresee Galafold as becoming the standard of care for Fabry disease patients with amenable mutations around the world. We think beyond this approval, Amicus has a robust pipeline." (2/26/2019)
Has Amicus Therapeutics been receiving favorable news coverage?
Press coverage about FOLD stock has trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amicus Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Amicus Therapeutics.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 31,370,000 shares, an increase of 5.3% from the August 30th total of 29,800,000 shares. Based on an average trading volume of 3,930,000 shares, the short-interest ratio is currently 8.0 days. Approximately 12.7% of the company's shares are sold short. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Amicus Therapeutics own?
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 52)
- Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
- Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
- Dr. Jay A. Barth, Chief Medical Officer (Age 55)
- Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.09%), Campbell & CO Investment Adviser LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Strs Ohio (0.00%) and First Midwest Bank Trust Division (0.00%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which major investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, First Midwest Bank Trust Division and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Hung Do, Jay Barth, John F Crowley and Michael Raab. View Insider Buying and Selling for Amicus Therapeutics.
Which major investors are buying Amicus Therapeutics stock?
FOLD stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Campbell & CO Investment Adviser LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $8.44.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $2.15 billion and generates $91.25 million in revenue each year. The biopharmaceutical company earns $-348,990,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.View Additional Information About Amicus Therapeutics.
What is Amicus Therapeutics' official website?
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
